Safeguarding<BR>every healthy future

Safeguarding
every healthy future

About

Established in 1986, EB Pharma is an integrated pharmaceutical company focused on sales and marketing. We maximize the value of innovator drug brands, which can begin from any stage of the product-life-cycle, by driving sales, increasing market share, and delivering share of voice, before finally purchasing carryover products should innovators choose to divest, or assisting in a planned withdrawl. In addtion to innovator products, we also carry a portfolio of generic products through contract research and toll manufacturing.

About
Values and Vision

Values and Vision

We collaborate with suppliers, distributors, and healthcare providers to provide products and services of the best quality to all patients. We emphasize integrity, performance, and teamwork, expecting our colleagues to aggressively engage in personal work, collaborating with team members and complying with changing corporate strategies, at the same time never compromising on business ethics.

Ethics and Compliance

To ensure the complaince of our business practices, all employees are required to sign and agree to the Code of Conduct and receive annual retraining. The Code of Conduct can be downloaded from the link below:

Download

Ethics and Compliance
Milestones

Milestones

  • 1986

    Established

  • 1990

    Started to market Zatiden for Northern Taiwan for Sandoz

  • 1993

    Started to market Voltaren for Northern Taiwan for Ciba-Geigy

  • 1996

    With Sandoz and Ciba-Geigy merged to become Novartis, EB Pharma became the largest distributor of Novartis in Taiwan, marketing more products such as Parlodel, Clozaril, Etumine, and Hydergine

  • 2003

    Started to develop own branded generic products in Taiwan

  • 2004

    Meto 250mg (Metformin) launched

  • 2005

    Suride 200mg (Sulpiride) launched

  • 2007

    Epram 10mg (Escitalopram) and Pane 40mg IV (Pantoprazole) launched

  • 2009

    Fute 0.5/5mg (Flupentixol) launched

  • 2011

    Epine 25/200/300mg (Quetiapine) launched

  • 2014

    Cibacen and Nitroderm TTS were added to our Novartis portfolio

  • 2016

    Trileptal and Tegretol were added to our Novartis portfolio

  • 2017

    Financial reports began to be audited by KPMG

  • 2018

    Ritalin IR and Ritalin LA were added to our Novartis portfolio

  • 2020

    Acquired Tofranil franchise in Taiwan

  • 2022

    Exelon was added to our Novartis portfolio; Ezole 2/5mg (Aripiprazole) launched; Exprexa 5/10mg (Olanzapine) launched; Exprexa 10mg Lyophilized Injection (Olanzapine) launched

  • 2023

    Gilenya and Mayzent were added to our Novartis portfolio

  • 2024

    Acquired Dalmadorm franchise in Taiwan; Revenue exceeded NT$ 1 billion